The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patientsHOCHHAUS, Andreas; KANTARJIAN, Hagop.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 12, pp 1971-1984, issn 0171-5216, 14 p.Article

Clinical Strategies to Achieve an Early and Successful Response to Tyrosine Kinase Inhibitor TherapyHUGHES, Timothy; HOCHHAUS, Andreas.Seminars in hematology. 2009, Vol 46, Num 2, issn 0037-1963, S11-S15, SUP3Article

Optimizing Therapy for Patients With Chronic Myelogenous Leukemia in Chronic PhaseKANTARJIAN, Hagop M; CORTES, Jorge; LA ROSEE, Paul et al.Cancer. 2010, Vol 116, Num 6, pp 1419-1430, issn 0008-543X, 12 p.Article

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinibKUMARI, Ashu; BRENDEL, Cornelia; HOCHHAUS, Andreas et al.Blood. 2012, Vol 119, Num 2, pp 530-539, issn 0006-4971, 10 p.Article

Clinical resistance to imatinib: mechanisms and implicationsHOCHHAUS, Andreas; HUGHES, Timothy.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, issn 0889-8588, ix, 641-656 [17 p.]Article

Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-αSCHMIDT, Manuel; HOCHHAUS, Andreas; NITSCHE, Andreas et al.Blood. 2001, Vol 97, Num 11, pp 3648-3650, issn 0006-4971Article

Diagnosis and management of chronic myeloid leukemia : A survey of american and european practice patternsKANTARJIAN, Hagop M; CORTES, Jorge; GUILHOT, Francois et al.Cancer. 2007, Vol 109, Num 7, pp 1365-1375, issn 0008-543X, 11 p.Article

Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD)SPIES-WEISSHART, Baerbel; SCHILLING, Kristina; BÖHMER, Frank et al.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 8, pp 1397-1404, issn 0171-5216, 8 p.Article

Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid LeukemiaCORTES, Jorge; HOCHHAUS, Andreas; HUGHES, Timothy et al.Journal of clinical oncology. 2011, Vol 29, Num 5, pp 524-531, issn 0732-183X, 8 p.Article

Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patientHOFHEINZ, Ralf-Dieter; NGUYEN, Xuan-Duc; BUCHHEIDT, Dieter et al.Cancer chemotherapy and pharmacology. 2004, Vol 53, Num 3, pp 276-277, issn 0344-5704, 2 p.Article

Results of comprehensive geriatric assessment effect survival in patients with malignant lymphomaWINKELMANN, Nils; PETERSEN, Iver; KIEHNTOPF, Michael et al.Journal of cancer research and clinical oncology. 2011, Vol 137, Num 4, pp 733-738, issn 0171-5216, 6 p.Article

BCR-ABL Mutations in Chronic Myeloid LeukemiaERNST, Thomas; LA ROSEE, Paul; MÜLLER, Martin C et al.Hematology/oncology clinics of North America. 2011, Vol 25, Num 5, issn 0889-8588, 997-1008, v-vi [14 p.]Article

Suitability of the PAXgene™ system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemiaERNST, Thomas; HOFFMANN, Jana; ERBEN, Philipp et al.Clinical chemistry and laboratory medicine. 2008, Vol 46, Num 3, pp 318-322, issn 1434-6621, 5 p.Article

Cytogenetic and molecular mechanisms of resistance to imatinibHOCHHAUS, Andreas.Seminars in hematology. 2003, Vol 40, Num 2, pp 69-79, issn 0037-1963, 11 p., SUP2Conference Paper

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVHEHLMANN, Rüdiger; MÜLLER, Martin C; SCHNITTGER, Susanne et al.Journal of clinical oncology. 2014, Vol 32, Num 5, pp 415-423, issn 0732-183X, 9 p.Article

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)KANTARJIAN, Hagop M; SHAH, Neil P; PAVLOVSKY, Carolina et al.Blood. 2012, Vol 119, Num 5, pp 1123-1129, issn 0006-4971, 7 p.Article

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNetGUILHOT, Joëlle; BACCARANI, Michele; ROUSSELOT, Philippe et al.Blood. 2012, Vol 119, Num 25, pp 5963-5971, issn 0006-4971, 9 p.Article

Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicityHÄRTEL, Nicolai; KLAG, Thomas; HANFSTEIN, Benjamin et al.Journal of cancer research and clinical oncology. 2012, Vol 138, Num 2, pp 203-212, issn 0171-5216, 10 p.Article

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinibCORTES, Jorge E; HOCHHAUS, Andreas; KANTARJIAN, Hagop M et al.Blood. 2011, Vol 117, Num 21, pp 5600-5606, issn 0006-4971, 7 p.Article

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid TumorsHOFHEINZ, Ralf-Dieter; AL-BATRAN, Salah-Eddin; HOCHHAUS, Andreas et al.Clinical cancer research (Print). 2010, Vol 16, Num 18, pp 4666-4674, issn 1078-0432, 9 p.Article

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaLE COUTRE, Philipp; OTTMANN, Oliver G; KULICZKOWSKI, Kazimierz et al.Blood. 2008, Vol 111, Num 4, pp 1834-1839, issn 0006-4971, 6 p.Article

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. CommentaryGUILHOT, Francois; APPERLEY, Jane; HEIM, Dominik et al.Blood. 2007, Vol 109, Num 10, issn 0006-4971, 4110, 4143-4150 [9 p.]Article

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2REITER, Andreas; WALZ, Christoph; VANSTRAELEN, Danny et al.Cancer research (Baltimore). 2005, Vol 65, Num 7, pp 2662-2667, issn 0008-5472, 6 p.Article

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaO'BRIEN, Stephen G; GUILHOT, Francois; LECHNER, Klaus et al.The New England journal of medicine. 2003, Vol 348, Num 11, pp 994-1004, issn 0028-4793, 11 p.Article

Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 studyHOCHHAUS, Andreas; LE COUTRE, Philipp D; KANTARJIAN, Hagop M et al.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 12, pp 1985-1993, issn 0171-5216, 9 p.Article